evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

504 questions · 511 findings · 66 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 104 · 20.4%GRADE not reported 26 · 5.1%Very low 107 · 20.9%Low 129 · 25.2%Moderate 107 · 20.9%High 38 · 7.4%

Intervention not reported

LDL‐Cholesterol rosuvastatin 2.5 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review

Intervention not reported

LDL‐Cholesterol rosuvastatin 5 mg/day · participantswith normal or abnormal lipid profiles
1 finding from 1 review

Probenecid vs allopurinol

Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) ‐ not measured · people with chronic gout

The review found no eligible studies for this question.

1 finding from 1 review

Benzbromarone vs probenecid

Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) · people with chronic gout

Benzbromarone probably leads to higher serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) compared with probenecid (moderate certainty).

1 finding from 1 review

Colchicine (0.5 mg three times per day) vs placebo

Improvement in oral ulcer score · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Colchicine (systemic; 0.5 mg three times daily for 6 months) showed no clear difference in improvement in oral ulcer score compared with placebo; GRADE not reported.

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Global state: No clinically significant response (as defined by the original studies) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

STANDARD LOWER DOSE (> 3 to 7.5 mg/day) vs OTHER DOSES

Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia

It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).

1 finding from 1 review

Intervention not reported

Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis

The intervention leads to higher etanercept (25 mg) + DMARD (high certainty).

1 finding from 1 review

Intervention not reported

Etanercept (25 mg) · participants with rheumatoid arthritis

The intervention leads to higher etanercept (25 mg) (high certainty).

1 finding from 1 review

Intervention not reported

Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis
1 finding from 1 review